Wabel Peter, Moissl Ulrich, Chamney Paul, Jirka Tomas, Machek Petr, Ponce Pedro, Taborsky Petr, Tetta Ciro, Velasco Nestor, Vlasak Jiri, Zaluska Wojciech, Wizemann Volker
Research & Development, Fresenius Medical Care D GmbH, Daimlerstrasse 15, D-61352 Bad Homburg, Germany.
Nephrol Dial Transplant. 2008 Sep;23(9):2965-71. doi: 10.1093/ndt/gfn228. Epub 2008 May 5.
Hypertension and fluid overload (FO) are well-recognized problems in the chronic kidney disease (CKD) population. While the prevalence of hypertension is well documented, little is known about the severity of FO in this population.
A new bioimpedance spectroscopy device (BCM-Body Composition Monitor) was selected that allows quantitative determination of the deviation in hydration status from normal ranges (DeltaHS). Pre-dialysis systolic blood pressure (BPsys) and DeltaHS was analysed in 500 haemodialysis patients from eight dialysis centres. A graphical tool (HRP-hydration reference plot) was devised allowing DeltaHS to be combined with measurements of BPsys enabling comparison with a matched healthy population (n = 1244).
Nineteen percent of patients (n = 95) were found to have normal BPsys and DeltaHS in the normal range. Approximately one-third of patients (n = 133) exhibited reasonable control of BPsys and fluids (BPsys <150 mmHg and DeltaHS <2.5 L). In only 15% of patients (n = 74) was hypertension observed (BPsys >150 mmHg) with a concomitant DeltaHS >2.5 L (possible volume-dependent hypertension). In contrast, 13% of patients (n = 69) were hypertensive with DeltaHS <1.1 L (possible essential hypertension). In 10% of patients (n = 52), BPsys <140 mmHg was recorded despite DeltaHS exceeding 2.5 L.
Our study illustrated the wide variability in BPsys regardless of the degree of DeltaHS. The HRP provides an invaluable tool for classifying patients in terms of BPsys and DeltaHS and the proximity of these parameters to reference ranges. This represents an important step towards more objective choice of strategies for the optimal treatment of hypertension and FO. Further studies are required to assess the prognostic and therapeutic role of the HRP.
高血压和液体超负荷(FO)是慢性肾脏病(CKD)人群中公认的问题。虽然高血压的患病率已有充分记录,但对于该人群中FO的严重程度却知之甚少。
选择了一种新的生物电阻抗光谱设备(BCM-人体成分监测仪),该设备可定量测定水合状态与正常范围的偏差(DeltaHS)。对来自8个透析中心的500例血液透析患者的透析前收缩压(BPsys)和DeltaHS进行了分析。设计了一种图形工具(HRP-水合参考图),使DeltaHS能够与BPsys的测量值相结合,从而与匹配的健康人群(n = 1244)进行比较。
19%的患者(n = 95)被发现BPsys正常且DeltaHS在正常范围内。约三分之一的患者(n = 133)表现出对BPsys和液体的合理控制(BPsys <150 mmHg且DeltaHS <2.5 L)。仅15%的患者(n = 74)观察到高血压(BPsys >150 mmHg),同时DeltaHS >2.5 L(可能为容量依赖性高血压)。相比之下,13%的患者(n = 69)患有高血压,DeltaHS <1.1 L(可能为原发性高血压)。10%的患者(n = 52)尽管DeltaHS超过2.5 L,但记录的BPsys <140 mmHg。
我们的研究表明,无论DeltaHS程度如何,BPsys都存在很大差异。HRP为根据BPsys和DeltaHS以及这些参数与参考范围的接近程度对患者进行分类提供了一个非常有价值的工具。这是朝着更客观地选择高血压和FO最佳治疗策略迈出的重要一步。需要进一步研究来评估HRP的预后和治疗作用。